BMS’ Camzyos (mavacamten) Receives NICE Recommendation for adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
- NICE has published its final guidance recommending BMS’ mavacamten for reimbursement and use across NHS in England and Wales as an add-on treatment option for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM)
- Mavacamten, a first-in-class selective, allosteric, and reversible cardiac myosin inhibitor received marketing authorization in Great Britain from MHRA and marketing authorization for Northern Ireland and the Republic of Ireland from the EC
- Additionally, the company continues to work with all relevant authorities & provides treatment access to eligible patients as quickly as possible via UK health services
Ref: Pharmiweb | Image: BMS
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.